Positive efficacy and safety data from a phase III trial of isavuconazole in patients with invasive aspergillosis have been presented at the European Congress of Clinical Microbiology and Infectious Diseases in Barcelona, Spain.
http://ift.tt/1lg1LSi
http://ift.tt/1lg1LSi
No comments:
Post a Comment